Taking this into account, Ladenburg Thalmann initiated its Traws Pharma Inc [TRAW] rating to a Buy in a research note published on March 01, 2022; the price target was $7. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering TRAW and reiterated its “Buy” recommendation on March 01, 2018. Maxim Group revised its rating on January 17, 2018. It rated TRAW as “a Hold” which previously was an “a Buy”.
Price Performance Review of TRAW
On Tuesday, Traws Pharma Inc [NASDAQ:TRAW] saw its stock fall -12.23% to $1.22. Over the last five days, the stock has lost -18.12%. Traws Pharma Inc shares have fallen nearly -86.26% since the year began. Nevertheless, the stocks have fallen -92.48% over the past one year. While a 52-week high of $19.44 was reached on 01/07/25, a 52-week low of $1.26 was recorded on 05/13/25. SMA at 50 days reached $2.0910, while 200 days put it at $5.5938.
Levels Of Support And Resistance For TRAW Stock
The 24-hour chart illustrates a support level at 1.0000, which if violated will result in even more drops to 0.7800. On the upside, there is a resistance level at 1.4900. A further resistance level may holdings at 1.7600. The Relative Strength Index (RSI) on the 14-day chart is 27.86, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.1188, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 70.18%. Stochastics %K at 21.39% indicates the stock is a holding.
The most recent change occurred on October 09, 2017 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $6 price target.
